Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1928-

  Crippa, S ^a,b   Partelli, S ^a,b   Boninsegna, L ^a,b   Falconi, M ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; KI 67 ANTIGEN; PLACEBO; SUNITINIB;

ADVANCED CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; ENDOCRINE TUMOR; HISTOPATHOLOGY; HUMAN; LETTER; MITOSIS INDEX; MULTIMODALITY CANCER THERAPY; PANCREATIC NEUROENDOCRINE TUMOR; POORLY DIFFERENTIATED ENDOCRINE CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR BIOPSY;

EID: 84864297629     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds166     Document Type: Letter

References (5)

1. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
2. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
3. Solcia E, Kloppel G, Sobin LH. Histological Typing of Endocrine Tumors, 2nd edition. Berlin: Springer 2000.
4. Nilsson O, Van Cutsem E, Delle Fave G et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006; 84: 212-215.
5. Rindi G, Arnold R, Bosman FT et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In Bosman FT, Carneiro F, Hruban RH, Theise ND (eds), WHO Classification of Tumors of the Digestive System, 4th edition. Lyon: IARC Press 2010; 13-14.